HUTCHMED (China) Limited (HCM) Description, Stock price, News & Info.

#ThinkSabio Latest News

HCM HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China